Catalyst Pharmaceuticals, Inc.
CPRX
$21.02
$0.150.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.26% | 25.33% | 23.23% | 15.40% | 81.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.26% | 25.33% | 23.23% | 15.40% | 81.98% |
| Cost of Revenue | 119.72% | -76.94% | 14.94% | 11.79% | -583.31% |
| Gross Profit | -31.01% | 2,084.28% | 24.81% | 16.07% | 305.67% |
| SG&A Expenses | 5.13% | 36.71% | 43.44% | 57.94% | 198.38% |
| Depreciation & Amortization | 3.15% | 10.11% | 10.08% | 43.07% | 1,461.90% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.67% | -44.39% | 29.46% | 43.46% | 129.92% |
| Operating Income | 50.73% | 236.90% | 16.16% | -23.82% | 35.36% |
| Income Before Tax | 58.82% | 250.46% | 15.00% | -22.04% | 41.50% |
| Income Tax Expenses | 53.80% | 283.56% | 39.48% | -24.93% | 57.40% |
| Earnings from Continuing Operations | 60.53% | 242.65% | 8.03% | -21.28% | 36.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.53% | 242.65% | 8.03% | -21.28% | 36.80% |
| EBIT | 50.73% | 236.90% | 16.16% | -23.82% | 35.36% |
| EBITDA | 42.23% | 310.90% | 15.22% | -13.39% | 61.81% |
| EPS Basic | 42.91% | 227.81% | -2.87% | -28.85% | 34.09% |
| Normalized Basic EPS | 39.29% | 232.64% | 7.61% | -29.56% | 27.98% |
| EPS Diluted | 41.39% | 220.69% | 0.00% | -26.92% | 34.61% |
| Normalized Diluted EPS | 40.95% | 225.76% | 9.15% | -28.01% | 30.38% |
| Average Basic Shares Outstanding | 12.35% | 11.60% | 11.22% | 10.65% | 2.04% |
| Average Diluted Shares Outstanding | 11.01% | 17.68% | 9.66% | 8.26% | 0.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
